---
document_datetime: 2025-12-25 13:17:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/orgalutran.html
document_name: orgalutran.html
version: success
processing_time: 0.1249453
conversion_datetime: 2025-12-29 19:35:38.195992
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Orgalutran

[RSS](/en/individual-human-medicine.xml/65969)

##### Authorised

This medicine is authorised for use in the European Union

ganirelix Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-82251)
- [More information on Orgalutran](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Orgalutran. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Orgalutran.

Expand section

Collapse section

## What is Orgalutran?

Orgalutran is a solution for injection in a prefilled syringe. Each syringe contains 0.25 mg of the active substance, ganirelix.

## What is Orgalutran used for?

Orgalutran is used to prevent premature ovulation (early release of eggs from the ovary) in women having fertility treatment and who are having ovarian stimulation (stimulation of the ovaries so that they produce more eggs). In premature ovulation, the ovaries release eggs that may be immature and not suitable for use in techniques such as in-vitro fertilisation.

The medicine can only be obtained with a prescription.

## How is Orgalutran used?

Treatment with Orgalutran should be carried out by a doctor who has experience in this type of fertility treatment.

Orgalutran is given as a single 0.25-mg injection under the skin once a day. Treatment should start on day 5 or 6 after the start of ovarian stimulation with follicle-stimulating hormone (FSH) or corifollitropin alfa (a modified FSH). When treatment should start depends on how well the ovaries are responding to stimulation. Treatment with Orgalutran should be continued up to the day that there are enough large follicles (small sacs in the ovary that hold the eggs).

Orgalutran is preferably given into the upper leg. The patient or her partner may give the injections themselves, if they have been trained and have access to expert advice. For further information on how to use Orgalutran, see the package leaflet.

## How does Orgalutran work?

The active substance in Orgalutran, ganirelix, blocks the receptors for a natural hormone called gonadotrophin-releasing hormone (GnRH). GnRH controls the secretion of another hormone called luteinising hormone (LH), which causes ovulation (the release of eggs during the menstrual cycle). During fertility treatment, ovarian stimulation is normally used to make the ovaries produce more than one egg. A few days later, a hormone called human chorionic gonadotrophin (hCG) is given to trigger ovulation, and the eggs are then harvested. By blocking the effect of GnRH, Orgalutran stops the production of LH, and therefore prevents premature ovulation.

## How has Orgalutran been studied?

The ability of Orgalutran to prevent premature ovulation has been studied in three main studies involving 1,335 women. Orgalutran was compared with buserelin, leuprorelin, and triptorelin (GnRH agonists: another group of medicines used to prevent premature ovulation, which work by stimulating the receptor for GnRH to such an extent that the body stops making LH). The main measures of effectiveness were the number of eggs that could be harvested and the number of women who became pregnant.

## What benefit has Orgalutran shown during the studies?

After treatment with Orgalutran, the average number of eggs that could be harvested was between 7.9 and 11.6 per woman. Between 20% and 31% of the women became pregnant. Overall, the values for the GnRH agonists were slightly higher.

## What is the risk associated with Orgalutran?

In studies, the most common side effect with Orgalutran (seen in more than 1 patient in 10) was a skin reaction at the injection site, mainly redness with or without swelling. For the full list of all side effects reported with Orgalutran, see the package leaflet.

Orgalutran should not be used in people who may be hypersensitive (allergic) to ganirelix, to any of the other ingredients, to GnRH or to other GnRH analogues (medicines that have a similar structure to GnRH and modify the activity of GnRH in the body). It must not be used by women who are pregnant or breast-feeding, or in women with moderate or severe kidney or liver disease. For the full list of restrictions, see the package leaflet.

Sometimes, the ovaries can over-respond to stimulation. This is called 'ovarian hyperstimulation syndrome'. Doctors and patients must be aware of this possibility.

## Why has Orgalutran been approved?

The CHMP decided that Orgalutran's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Orgalutran

The European Commission granted a marketing authorisation valid throughout the European Union for Orgalutran to N.V. Organon on 17 May 2000. The marketing authorisation is valid for an unlimited period.

For more information about treatment with Orgalutran, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Orgalutran : EPAR - Summary for the public

English (EN) (68.29 KB - PDF)

**First published:** 02/10/2006

**Last updated:** 11/04/2011

[View](/en/documents/overview/orgalutran-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-467)

български (BG) (170.31 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/bg/documents/overview/orgalutran-epar-summary-public_bg.pdf)

español (ES) (129.43 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/es/documents/overview/orgalutran-epar-summary-public_es.pdf)

čeština (CS) (98.72 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/cs/documents/overview/orgalutran-epar-summary-public_cs.pdf)

dansk (DA) (71.24 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/da/documents/overview/orgalutran-epar-summary-public_da.pdf)

Deutsch (DE) (86.06 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/de/documents/overview/orgalutran-epar-summary-public_de.pdf)

eesti keel (ET) (68.57 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/et/documents/overview/orgalutran-epar-summary-public_et.pdf)

ελληνικά (EL) (178.02 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/el/documents/overview/orgalutran-epar-summary-public_el.pdf)

français (FR) (134.11 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/fr/documents/overview/orgalutran-epar-summary-public_fr.pdf)

italiano (IT) (72.05 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/it/documents/overview/orgalutran-epar-summary-public_it.pdf)

latviešu valoda (LV) (159.33 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/lv/documents/overview/orgalutran-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (96.11 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/lt/documents/overview/orgalutran-epar-summary-public_lt.pdf)

magyar (HU) (94.83 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/hu/documents/overview/orgalutran-epar-summary-public_hu.pdf)

Malti (MT) (97.08 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/mt/documents/overview/orgalutran-epar-summary-public_mt.pdf)

Nederlands (NL) (148 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/nl/documents/overview/orgalutran-epar-summary-public_nl.pdf)

polski (PL) (159.58 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/pl/documents/overview/orgalutran-epar-summary-public_pl.pdf)

português (PT) (132.38 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/pt/documents/overview/orgalutran-epar-summary-public_pt.pdf)

română (RO) (156.57 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/ro/documents/overview/orgalutran-epar-summary-public_ro.pdf)

slovenčina (SK) (157.86 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/sk/documents/overview/orgalutran-epar-summary-public_sk.pdf)

slovenščina (SL) (153.66 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/sl/documents/overview/orgalutran-epar-summary-public_sl.pdf)

Suomi (FI) (70.45 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/fi/documents/overview/orgalutran-epar-summary-public_fi.pdf)

svenska (SV) (130.96 KB - PDF)

**First published:**

02/10/2006

**Last updated:**

11/04/2011

[View](/sv/documents/overview/orgalutran-epar-summary-public_sv.pdf)

Orgalutran : EPAR - Risk management plan

English (EN) (371.04 KB - PDF)

**First published:** 30/05/2024

[View](/en/documents/rmp/orgalutran-epar-risk-management-plan_en.pdf)

## Product information

Orgalutran : EPAR - Product information

English (EN) (250.42 KB - PDF)

**First published:** 29/02/2008

**Last updated:** 18/12/2025

[View](/en/documents/product-information/orgalutran-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-527)

български (BG) (296.01 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/bg/documents/product-information/orgalutran-epar-product-information_bg.pdf)

español (ES) (225.28 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/es/documents/product-information/orgalutran-epar-product-information_es.pdf)

čeština (CS) (295.8 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/cs/documents/product-information/orgalutran-epar-product-information_cs.pdf)

dansk (DA) (225.6 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/da/documents/product-information/orgalutran-epar-product-information_da.pdf)

Deutsch (DE) (270.72 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/de/documents/product-information/orgalutran-epar-product-information_de.pdf)

eesti keel (ET) (251.33 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/et/documents/product-information/orgalutran-epar-product-information_et.pdf)

ελληνικά (EL) (302.28 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/el/documents/product-information/orgalutran-epar-product-information_el.pdf)

français (FR) (295.34 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/fr/documents/product-information/orgalutran-epar-product-information_fr.pdf)

hrvatski (HR) (297.24 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/hr/documents/product-information/orgalutran-epar-product-information_hr.pdf)

íslenska (IS) (251.38 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/is/documents/product-information/orgalutran-epar-product-information_is.pdf)

italiano (IT) (341.92 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/it/documents/product-information/orgalutran-epar-product-information_it.pdf)

latviešu valoda (LV) (302.24 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/lv/documents/product-information/orgalutran-epar-product-information_lv.pdf)

lietuvių kalba (LT) (285.22 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/lt/documents/product-information/orgalutran-epar-product-information_lt.pdf)

magyar (HU) (299.38 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/hu/documents/product-information/orgalutran-epar-product-information_hu.pdf)

Malti (MT) (313.35 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/mt/documents/product-information/orgalutran-epar-product-information_mt.pdf)

Nederlands (NL) (231.14 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/nl/documents/product-information/orgalutran-epar-product-information_nl.pdf)

norsk (NO) (360.29 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/no/documents/product-information/orgalutran-epar-product-information_no.pdf)

polski (PL) (394.18 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/pl/documents/product-information/orgalutran-epar-product-information_pl.pdf)

português (PT) (249.37 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/pt/documents/product-information/orgalutran-epar-product-information_pt.pdf)

română (RO) (389.45 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/ro/documents/product-information/orgalutran-epar-product-information_ro.pdf)

slovenčina (SK) (287.42 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/sk/documents/product-information/orgalutran-epar-product-information_sk.pdf)

slovenščina (SL) (268.38 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/sl/documents/product-information/orgalutran-epar-product-information_sl.pdf)

Suomi (FI) (237.72 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/fi/documents/product-information/orgalutran-epar-product-information_fi.pdf)

svenska (SV) (238.14 KB - PDF)

**First published:**

29/02/2008

**Last updated:**

18/12/2025

[View](/sv/documents/product-information/orgalutran-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000318971 18/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Orgalutran : EPAR - All Authorised presentations

English (EN) (51.62 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 19/05/2016

[View](/en/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-166)

български (BG) (53.56 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/bg/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_bg.pdf)

español (ES) (51.42 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/es/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52.69 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/cs/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (53.37 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/da/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (52.79 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/de/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (60.85 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/et/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (52.34 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/el/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_el.pdf)

français (FR) (51.07 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/fr/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (50.9 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/hr/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (51.95 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/is/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.61 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/it/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.96 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/lv/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (51.73 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/lt/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (51.49 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/hu/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (51.99 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/mt/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (51.16 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/nl/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (52.58 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/no/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_no.pdf)

polski (PL) (52.52 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/pl/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_pl.pdf)

português (PT) (52.16 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/pt/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_pt.pdf)

română (RO) (50.96 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/ro/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.6 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/sk/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (50.46 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/sl/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (49.67 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/fi/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (51.25 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

19/05/2016

[View](/sv/documents/all-authorised-presentations/orgalutran-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Orgalutran Active substance ganirelix International non-proprietary name (INN) or common name ganirelix Therapeutic area (MeSH)

- Reproductive Techniques, Assisted
- Ovulation Induction
- Infertility, Female

Anatomical therapeutic chemical (ATC) code H01CC01

### Pharmacotherapeutic group

Pituitary and hypothalamic hormones and analogues

### Therapeutic indication

The prevention of premature luteinising-hormone surges in women undergoing controlled ovarian hyperstimulation for assisted reproduction techniques.

In clinical studies, Orgalutran was used with recombinant human follicle-stimulating hormone or corifollitropin alfa, the sustained follicle stimulant.

## Authorisation details

EMA product number EMEA/H/C/000274 Marketing authorisation holder

N.V. Organon

Kloosterstraat 6

Opinion adopted 17/05/2000 Marketing authorisation issued 16/05/2000 Revision 26

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Orgalutran : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.89 KB - PDF)

**First published:** 18/12/2025

[View](/en/documents/procedural-steps-after/orgalutran-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Orgalutran : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (205.95 KB - PDF)

**First published:** 29/02/2008

**Last updated:** 18/12/2025

[View](/en/documents/procedural-steps-after/orgalutran-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Orgalutran : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (74.13 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/steps-after-cutoff/orgalutran-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Orgalutran : EPAR - Scientific Discussion

English (EN) (233.63 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/orgalutran-epar-scientific-discussion_en.pdf)

Orgalutran : EPAR - Procedural steps taken before authorisation

English (EN) (92.2 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/orgalutran-epar-procedural-steps-taken-authorisation_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Orgalutran : EPAR - Product information - tracked changes

English (EN) (87.62 KB - DOCX)

**First published:** 18/12/2025

[View](/en/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-827)

български (BG) (221 KB - DOC)

**First published:**

18/12/2025

[View](/bg/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_bg.doc)

español (ES) (188.5 KB - DOC)

**First published:**

18/12/2025

[View](/es/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_es.doc)

čeština (CS) (209.5 KB - DOC)

**First published:**

18/12/2025

[View](/cs/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_cs.doc)

dansk (DA) (83.96 KB - DOCX)

**First published:**

18/12/2025

[View](/da/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (85.1 KB - DOCX)

**First published:**

18/12/2025

[View](/de/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (190 KB - DOC)

**First published:**

18/12/2025

[View](/et/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_et.doc)

ελληνικά (EL) (92.3 KB - DOCX)

**First published:**

18/12/2025

[View](/el/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_el.docx)

français (FR) (191.5 KB - DOC)

**First published:**

18/12/2025

[View](/fr/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_fr.doc)

hrvatski (HR) (82.3 KB - DOCX)

**First published:**

18/12/2025

[View](/hr/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (186 KB - DOC)

**First published:**

18/12/2025

[View](/is/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_is.doc)

italiano (IT) (182.5 KB - DOC)

**First published:**

18/12/2025

[View](/it/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_it.doc)

latviešu valoda (LV) (81.45 KB - DOCX)

**First published:**

18/12/2025

[View](/lv/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (89.05 KB - DOCX)

**First published:**

18/12/2025

[View](/lt/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (92.65 KB - DOCX)

**First published:**

18/12/2025

[View](/hu/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (97.25 KB - DOCX)

**First published:**

18/12/2025

[View](/mt/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (195 KB - DOC)

**First published:**

18/12/2025

[View](/nl/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_nl.doc)

norsk (NO) (186.5 KB - DOC)

**First published:**

18/12/2025

[View](/no/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_no.doc)

polski (PL) (87.89 KB - DOCX)

**First published:**

18/12/2025

[View](/pl/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_pl.docx)

português (PT) (84.81 KB - DOCX)

**First published:**

18/12/2025

[View](/pt/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_pt.docx)

română (RO) (85.83 KB - DOCX)

**First published:**

18/12/2025

[View](/ro/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (240.5 KB - DOC)

**First published:**

18/12/2025

[View](/sk/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_sk.doc)

slovenščina (SL) (83.88 KB - DOCX)

**First published:**

18/12/2025

[View](/sl/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (80.62 KB - DOCX)

**First published:**

18/12/2025

[View](/fi/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (80.85 KB - DOCX)

**First published:**

18/12/2025

[View](/sv/documents/product-information-tracked-changes/orgalutran-epar-product-information-tracked-changes_sv.docx)

#### More information on Orgalutran

- [Orgalutran - supply shortage](/en/medicines/human/shortages/orgalutran)
- [Post-marketing Observational Study to Characterize the Safety and Effectiveness Profile of Orgalutran® in Chinese Women Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproduction Techniques (MK-8761-050) - post-authorisation study](https://catalogues.ema.europa.eu/study/22133)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/12/2025

## Share this page

[Back to top](#main-content)